Invitrogen

CCL5 (RANTES) Monoclonal Antibody, PeproTech®

CCL5 (RANTES) Antibody in Western Blot (WB)

FIGURE: 1 / 5

CCL5 (RANTES) Antibody (500-M75-500UG) in WB

Western Blot: To detect Human RANTES (CCL5) by Western Blot analysis CCL5 (RANTES) Monoclonal Antibody (Product # 500-M75-500UG) can be used at a concentration of 0.5-1.0 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human RANTES (CCL5) is 0.25-2.0 ng/lane, under reducing conditions and 0.25-0.5 ng/lane, under non-reducing conditions.

CCL5 (RANTES) Antibody in Neutralization (Neu)

Product Image Gallery

Product Details

500-M75-500UG

Applications

Tested Dilution

Publications

Western Blot (WB)

0.5-1.0 µg/mL

View 1 publication 1 publication

Immunohistochemistry (IHC)

View 1 publication 1 publication

ELISA (ELISA)

2.0-4.0 µg/mL

View 5 publications 5 publications

Neutralization (Neu)

View 1 publication 1 publication

In vitro Assay (IV)

View 3 publications 3 publications

Immunostaining (IS)

View 4 publications 4 publications

Product Specifications

Species Reactivity

Human

Published species

Human, Mouse

Host/Isotype

Mouse

Class

Monoclonal

Type

Antibody

Immunogen

E.coli-derived Recombinant Human RANTES (CCL5)

View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

1 mg/mL

Purification

Protein A

Storage buffer

PBS

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

RRID

AB_2929127

Product Specific Information

AA Sequence of recombinant protein: SPYSSDTTPC CFAYIARPLP RAHIKEYFYT SGKCSNPAVV FVTRKNRQVC ANPEKKWVRE YINSLEMS.

Preparation: Produced in BALB/c mice immunized with highly pure Recombinant Human RANTES (CCL5). Anti-Human RANTES (CCL5)-specific antibody was purified from ascites fluid by Protein A affinity chromatography.

Sandwich ELISA: Assuming 100 µL/well, a concentration of 2.0-4.0 µg/mL of this antibody will detect at least 500 pg/mL of Recombinant Human RANTES (CCL5) when used with PeproTech Biotinylated Antigen Affinity Purified Anti-Human RANTES (CCL5) (500-P36BT) as the detection antibody at a concentration of approximately 0.5-1.0 µg/mL.

Western Blot: To detect Human RANTES (CCL5) by Western Blot analysis this antibody can be used at a concentration of 0.5-1.0 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human RANTES (CCL5) is 0.25-2.0 ng/lane, under reducing conditions and 0.25-0.5 ng/lane, under non-reducing conditions.

Target Information

CCL5 (RANTES) is a chemokine gene located on the q-arm of chromosome 17. Chemokines are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of the N-terminal cysteine residues of the mature peptide. CCL5, a member of the CC subfamily, functions as a chemoattractant for blood monocytes, memory T helper cells, and eosinophils. It causes the release of histamine from basophils and activates eosinophils. This cytokine is one of the major HIV-suppressive factors produced by CD8+ cells. It functions as one of the natural ligands for the chemokine receptor chemokine (C-C motif) receptor 5 (CCR5), and it suppresses in vitro replication of the R5 strains of HIV-1, which use CCR5 as a coreceptor. Alternative splicing results in multiple transcript variants that encode different isoforms. Diseases associated with CCL5 include Human Immunodeficiency Virus Type 1 and Periapical Granuloma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes.

Cancers

Erlichman N,Baram T,Meshel T,Morein D,Da'adoosh B,Ben-Baruch A

500-M75 was used in Enzyme-linked immunosorbent assay to investigate the role of WT-PD-L1 in triple-negative breast cancer.

Fri Feb 18 00:00:00 EST 2022

Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.

Frontiers in immunology

Liubomirski Y,Lerrer S,Meshel T,Morein D,Rubinstein-Achiasaf L,Sprinzak D,Wiemann S,Körner C,Ehrlich M,Ben-Baruch A

500-M75 was used in Enzyme-linked immunosorbent assay to investigate pro-metastatic chemokines in triple-negative breast cancer.

Thu Oct 01 00:00:00 EDT 2020

Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.

Frontiers in immunology

Liubomirski Y,Lerrer S,Meshel T,Rubinstein-Achiasaf L,Morein D,Wiemann S,Körner C,Ben-Baruch A

500-M75 was used in Enzyme-linked immunosorbent assay to study the impact of tumor-stroma-inflammation networks on pro-metastatic phenotypes in triple-negative breast cancer (TNBC) to identify a novel tumor-stroma-inflammation networks that may promote TNBC aggressiveness by increasing the pro-malignancy potential of the TME and of the tumor cells themselves, and reveal key roles for CXCL8 in mediating these metastasis-promoting activities.

Mon Aug 10 00:00:00 EDT 2020

Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop.

Oncotarget

Lin S,Sun L,Lyu X,Ai X,Du D,Su N,Li H,Zhang L,Yu J,Yuan S

500-M75 was used in In vitro experiments to show that lactate activated human macrophages to a tumor-associated macrophage (TAM)-like phenotype and stimulated the secretion of CCL5 by activation of Notch signaling in macrophages.

Fri Dec 15 00:00:00 EST 2017

Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop.

Oncotarget

Lin S,Sun L,Lyu X,Ai X,Du D,Su N,Li H,Zhang L,Yu J,Yuan S

Fri Dec 15 00:00:00 EST 2017

Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop.

Oncotarget

Lin S,Sun L,Lyu X,Ai X,Du D,Su N,Li H,Zhang L,Yu J,Yuan S

Fri Dec 15 00:00:00 EST 2017

Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.

Stem cell research & therapy

Katanov C,Lerrer S,Liubomirski Y,Leider-Trejo L,Meshel T,Bar J,Feniger-Barish R,Kamer I,Soria-Artzi G,Kahani H,Banerjee D,Ben-Baruch A

500-M75 was used in Enzyme-linked immunosorbent assay to study the impact of tumour necrosis factor α and interleukin 1β on the inflammatory phenotype of cancer-associated fibroblasts and mesenchymal stem cells.

Fri May 01 00:00:00 EDT 2015

Tumor-promoting circuits that regulate a cancer-related chemokine cluster: dominance of inflammatory mediators over oncogenic alterations.

Cancers

Leibovich-Rivkin T,Buganim Y,Solomon H,Meshel T,Rotter V,Ben-Baruch A

500-M75 was used in Enzyme-linked immunosorbent assay to use an unbiased model system to propose that inflammatory mediators of the tumor milieu have dominating roles over oncogenic modifications in dictating the expression of a pro-malignancy chemokine readout.

Fri Jan 20 00:00:00 EST 2012

Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.

BMC cancer

Soria G,Ofri-Shahak M,Haas I,Yaal-Hahoshen N,Leider-Trejo L,Leibovich-Rivkin T,Weitzenfeld P,Meshel T,Shabtai E,Gutman M,Ben-Baruch A

500-M75 was used in Immunohistochemistry to determine whether there are associations between inflammatory chemokines CCL2 (MCP-1) CCL5 (RANTES) and the inflammatory cytokines TNFα IL-1β along stages of breast cancer progression, and to identify the possible implications of these factors to disease course.

Tue Apr 12 00:00:00 EDT 2011

Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.

BMC cancer

Soria G,Ofri-Shahak M,Haas I,Yaal-Hahoshen N,Leider-Trejo L,Leibovich-Rivkin T,Weitzenfeld P,Meshel T,Shabtai E,Gutman M,Ben-Baruch A

Tue Apr 12 00:00:00 EDT 2011

The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research

Yaal-Hahoshen N,Shina S,Leider-Trejo L,Barnea I,Shabtai EL,Azenshtein E,Greenberg I,Keydar I,Ben-Baruch A

Tue Aug 01 00:00:00 EDT 2006

The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.

Cancer research

Azenshtein E,Luboshits G,Shina S,Neumark E,Shahbazian D,Weil M,Wigler N,Keydar I,Ben-Baruch A

Fri Feb 15 00:00:00 EST 2002

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.

Cancer research

Luboshits G,Shina S,Kaplan O,Engelberg S,Nass D,Lifshitz-Mercer B,Chaitchik S,Keydar I,Ben-Baruch A

Wed Sep 15 00:00:00 EDT 1999

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.

Cancer research

Luboshits G,Shina S,Kaplan O,Engelberg S,Nass D,Lifshitz-Mercer B,Chaitchik S,Keydar I,Ben-Baruch A

Wed Sep 15 00:00:00 EDT 1999

Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains.

The American journal of pathology

Xia MQ,Qin SX,Wu LJ,Mackay CR,Hyman BT

Wed Jul 01 00:00:00 EDT 1998

Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains.

The American journal of pathology

Xia MQ,Qin SX,Wu LJ,Mackay CR,Hyman BT

Wed Jul 01 00:00:00 EDT 1998

Bioinformatics

Protein Aliases: beta-chemokine RANTES; C-C motif chemokine 5; chemokine (C-C motif) ligand 5; EoCP; Eosinophil chemotactic cytokine; MGC17164; OTTHUMP00000197106; regulated upon activation, normally T-expressed, and presumably secreted; SIS δ; SIS-delta; SISδ; small inducible cytokine subfamily A (Cys-Cys), member 5; Small-inducible cytokine A5; T cell-specific protein P228; T-cell specific protein p288; T-cell-specific protein RANTES; TCP228

View more View less

Gene Aliases: CCL5; D17S136E; eoCP; RANTES; SCYA5; SIS-delta; SISd; TCP228

View more View less

UniProt ID: (Human) P13501

View more View less

Entrez Gene ID: (Human) 6352

View more View less

Function(s)

phosphatidylinositol phospholipase C activity protein kinase activity protein binding chemokine activity heparin binding phospholipase activator activity receptor signaling protein tyrosine kinase activator activity CCR1 chemokine receptor binding CCR4 chemokine receptor binding CCR5 chemokine receptor binding chemoattractant activity chemokine receptor binding protein homodimerization activity protein self-association chemokine receptor antagonist activity cytokine intercellular signal molecule

Process(es)

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

CCL5 (RANTES) Monoclonal Antibody, PeproTech®

CCL5 (RANTES) Antibody (500-M75-500UG) in WB

Product Details

500-M75-500UG

Western Blot (WB)

Immunohistochemistry (IHC)

ELISA (ELISA)

Neutralization (Neu)

In vitro Assay (IV)

Immunostaining (IS)

Species Reactivity

Published species

Host/Isotype

Class

Type

Immunogen

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!